關於 VELOXIS PHARMACEUTICALS, INC.
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Hørsholm, Denmark, with an office in Cary, North Carolina.
Source: Wikipedia
總部2000 Regency Parkway, 27518, Cary, US
成立時間2016
狀態營運中
專利5 項專利
Stabilized tacrolimus compositionUS12403095B2 · 2025
STABILIZED TACROLIMUS COMPOSITIONUS2023101012A1 · 2023
法律資訊
| 法定名稱 | VELOXIS PHARMACEUTICALS, INC. |
|---|---|
| LEI | 549300YD7MO7TUE8GX79在 GLEIF 上查看 ↗ |
| 登記地址 | 2000 Regency Parkway, 27518, Cary, US |
| 狀態 | 營運中 |
來源: GLEIF · 更新於 2026年10月16日